Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland
Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.
BMJ Open. 2024 Mar 28;14(3):e078890. doi: 10.1136/bmjopen-2023-078890.
To determine the prevalence and incidence of polypharmacy/hyperpolypharmacy and which medications are most prescribed to patients with varying burden of polypharmacy.
Retrospective, population-based cohort study.
Iceland.
Including patients (≥18 years) admitted to internal medicine services at Landspitali - The National University Hospital of Iceland, between 1 January 2010 with a follow-up of clinical outcomes through 17 March 2022.
Participants were categorised into medication use categories of non-polypharmacy (<5), polypharmacy (5-10) and hyperpolypharmacy (>10) based on the number of medications filled in the year predischarge and postdischarge. The primary outcome was prevalence and incidence of new polypharmacy. Secondary outcomes were mortality, length of hospital stay and re-admission.
Among 85 942 admissions (51% male), the median (IQR) age was 73 (60-83) years. The prevalence of preadmission non-polypharmacy was 15.1% (95% CI 14.9 to 15.3), polypharmacy was 22.9% (95% CI 22.6 to 23.2) and hyperpolypharmacy was 62.5% (95% CI 62.2 to 62.9). The incidence of new postdischarge polypharmacy was 33.4% (95% CI 32.9 to 33.9), and for hyperpolypharmacy was 28.9% (95% CI 28.3 to 29.5) for patients with preadmission polypharmacy. Patients with a higher level of medication use were more likely to use multidose drug dispensing and have a diagnosis of adverse drug reaction. Other comorbidities, including responsible subspeciality and estimates of comorbidity and frailty burden, were identical between groups of varying polypharmacy. There was no difference in length of stay, re-admission rate and mortality.
Preadmission polypharmacy/hyperpolypharmacy and postdischarge new polypharmacy/hyperpolypharmacy is common amongst patients admitted to internal medicine. A higher level of medication use category was not found to be associated with demographic, comorbidity and clinical outcomes. Medications that are frequently inappropriately prescribed were among the most prescribed medications in the group. An increased focus on optimising medication usage is needed after hospital admission.
NCT05756400.
确定多药治疗/超多药治疗的流行率和发生率,以及哪些药物最常开给不同多药治疗负担的患者。
回顾性、基于人群的队列研究。
冰岛。
包括 2010 年 1 月 1 日至 2022 年 3 月 17 日期间在冰岛国家大学医院 Landspitali-内科学服务部门住院的患者(≥18 岁),并通过临床结局随访。
根据出院前和出院后一年内用药数量,患者被分为非多药治疗(<5)、多药治疗(5-10)和超多药治疗(>10)用药类别。主要结局是新的多药治疗的流行率和发生率。次要结局是死亡率、住院时间和再入院。
在 85942 例住院患者中(51%为男性),中位(IQR)年龄为 73(60-83)岁。入院前非多药治疗的患病率为 15.1%(95%CI 14.9 至 15.3),多药治疗为 22.9%(95%CI 22.6 至 23.2),超多药治疗为 62.5%(95%CI 62.2 至 62.9)。新的出院后多药治疗的发生率为 33.4%(95%CI 32.9 至 33.9),对于入院前有多药治疗的患者,超多药治疗的发生率为 28.9%(95%CI 28.3 至 29.5)。用药水平较高的患者更有可能使用多剂量药物配给,并伴有药物不良反应的诊断。其他合并症,包括负责的亚专科以及合并症和虚弱负担的估计,在不同多药治疗组之间是相同的。住院时间、再入院率和死亡率没有差异。
内科住院患者中,入院前多药治疗/超多药治疗和出院后新发多药治疗/超多药治疗很常见。较高的用药类别水平与人口统计学、合并症和临床结局无关。经常开具不当的药物是最常开具的药物之一。在住院后需要更加关注优化药物使用。
NCT05756400。